Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Johnson and Johnson
Express Scripts
McKesson

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Ivosidenib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for ivosidenib and what is the scope of patent protection?

Ivosidenib is the generic ingredient in one branded drug marketed by Agios Pharms Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivosidenib has sixty patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for ivosidenib
International Patents:60
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 28
Clinical Trials: 9
Patent Applications: 25
DailyMed Link:ivosidenib at DailyMed
Recent Clinical Trials for ivosidenib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers Squibb (BMS)Phase 2
Academic and Community Cancer Research UnitedPhase 1
Jason LukePhase 2

See all ivosidenib clinical trials

Synonyms for ivosidenib
(2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-glycinamide
(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
(S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
(S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-
(S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
1448347-49-6
A14386
AG-120
ag-120-Ivosidenib
AG120
AS-35058
CHEMBL3989958
CS-5122
D11090
EX-A992
Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)-
GTPL9217
HY-18767
Ivosidenib (AG-120)
Ivosidenib (USAN/INN)
Ivosidenib [INN]
Ivosidenib [USAN]
Ivosidenib [WHO-DD]
MFCD29036964
NCGC00476170-04
NCGC00476170-06
Q2PCN8MAM6
RG120
s8206
SCHEMBL15122512
Tibsovo
UNII-Q2PCN8MAM6
ZINC205136523

US Patents and Regulatory Information for ivosidenib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKesson
Baxter
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.